Electromed, Inc.

ELMD

NYSE; healthcare; SIC 3845, Electromedical & Electrotherapeutic Apparatus; CIK 0001488917

A

strongest fifth of 370 graded peers in healthcare

rank 14 of 370; percentile 3.5; sampling error 2.5 points; lower is stronger

A B C D E

A, the bull



Scoreboard	
Profitability	B percentile 36.0
Solvency	B percentile 23.6
Growth and financing	B percentile 28.3
Reliability	0.83 AUC filers with $12.5M to $120M assets; 95% interval 0.79 to 0.86; 201 events, 2020 to 2025
Peer failure rate	1.07% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	$12.5M to $120M assets total assets $66.3M
Standard universe	inside revenue above $1M and assets above $10M
Warnings	none triggered; fortress balance sheet not computable: distress
Inputs computable	9 of 14
Graded from	filings received through Aug 25, 2026 62 days before the rescan; latest periodic filing 10-K received Aug 25, 2026
Last close	$26.54 2026-10-23; market equity $222.0M; no price enters the letter

Share price, twelve months to the rescan



Split-adjusted close. Each lollipop is a rescan and carries the letter held then.

Letter at every rescan, 2012 to 2026



Sector percentile at each rescan, stronger toward the top; facts filed by each date only.

Business, in the company's words

opening of Item 1 of the 10-K received Aug 25, 2026

Electromed, Inc. ("we," "our," "us," "Electromed" or the "Company") develops, manufactures, markets and sells innovative products that provide airway clearance therapy, including the SmartVest® Airway Clearance System ("SmartVest System") to patients with compromised pulmonary function with a commitment to excellence and compassionate service. Our goal is to make High Frequency Chest Wall Oscillation ("HFCWO") treatments as effective, convenient, and comfortable as possible, so our patients can breathe easier and live better with improved respiratory function and fewer exacerbations.

The fourteen inputs

lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight

Input	Value	Peer median	Percentile, 0 to 100	Pct	Peers	Period end
Profitability, sleeve percentile 36.0						
Gross profitability	87.4%	32.3%		5.7	368	2026-06-30
Return on invested capital	not computable	9.3%				

latest aligned inputs end 2015-06-30; latest annual assets end 2026-06-30

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Accruals ratio	2.7%	(6.6%)	84.5	807	2026-06-30
Gross margin stability, five years	1.2 pts	2.8 pts	17.8	242	2026-06-30
Solvency, sleeve percentile 23.6					
Twelve-month failure probability	not computable	0.07%			
latest liabilities, cash plus short-term investments, book equity, and shares are required					
Altman Z double-prime	11.89	(0.33)	7.6	752	2026-06-30
Net debt to EBITDA	not computable	1.82x			
latest aligned inputs end 2015-06-30; latest annual assets end 2026-06-30					
Interest coverage	not computable	(4.51x)			
interest expense must exceed $100,000					
Current ratio	4.69x	2.94x	39.6	834	2026-06-30
Growth and financing, sleeve percentile 28.3					
Revenue growth, three-year compound	15.4%	10.1%	39.1	413	2026-06-30
Free cash flow growth, three-year compound	not computable	10.9%			
current FCF must be positive and base FCF must exceed $100,000					
Reinvestment rate	99.9%	37.1%	32.0	104	2026-06-30
Asset growth, three years	13.1%	2.1%	27.8	700	2026-06-30
Net share issuance, one year	0.2%	2.5%	14.2	636	2026-08-19

Warnings

1 of 7 checks triggered; none of them enters the letter

Check	Measured
Fortress balance sheet	cash minus debt is 2,347,240 USD; Altman Z is not used

Among 370 peers

healthcare; letters are fifths of this list



Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.

Rank	Company	Percentile	Letter	Warnings
9	Exelixis, Inc. (EXEL)	2.2	A	fortress balance sheet
10	Iradimed Corp. (IRMD)	2.4	A	
11	Castle Biosciences Inc. (CSTL)	2.7	A	fortress balance sheet
12	Penumbra Inc. (PEN)	3.0	A	
13	Lemaitre Vascular Inc. (LMAT)	3.3	A	
14	Electromed, Inc. (ELMD)	3.5	A	fortress balance sheet
15	Tactile Systems Technology Inc. (TCMD)	3.8	A	fortress balance sheet
16	Corcept Therapeutics Inc. (CORT)	4.1	A	fortress balance sheet
17	Ideaya Biosciences, Inc. (IDYA)	4.3	A	
18	Tarsus Pharmaceuticals, Inc. (TARS)	4.6	A	fortress balance sheet
19	Vericel Corp. (VCEL)	4.9	A	

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

What the price implies

at the 2026-10-23 close; none of these enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	13.9%	7.7%	54
Distance from 52-week high	(43.1%)	(31.4%)	34
EBIT to enterprise value	6.9%	(1.5%)	86
Free cash flow yield	3.8%	(1.0%)	74
Book value to price	0.24	0.28	46
Sales to price	0.33	0.30	52
Composite equity issuance, five years	(2.6%)	20.5%	23
Relative strength against the sector, log excess return	(0.08)	(0.14)	54

Diagnostics

shown on every report; none enters the grade

Measure	Value
Piotroski F-score None of 9, period end 2026-06-30	
Return on assets above zero	pass
Operating cash flow above zero	pass
Return on assets improved	pass
Operating cash flow exceeds net income	fail
Long-term leverage fell	fail
Current ratio improved	pass
No new shares issued	fail
Gross margin improved	pass
Asset turnover improved	pass
Cash, filings, liquidity	
Cash and equivalents	$20.4M
Operating cash flow, four quarters	$9.7M
Months of runway	not finite
Days since last periodic filing	62 (10-K received Aug 25, 2026)
Median daily dollar volume, 63 sessions	$2.4M

Sources

every fact behind the inputs; each row links to its filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	gross profit	us-gaap:GrossProfit	$57.9M	2026-06-30	2026-08-25	10-K	26-028914
2	assets	us-gaap:Assets	$66.3M	2026-06-30	2026-08-25	10-K	26-028914
3	operating income	us-gaap:OperatingIncomeLoss	$1.3M	2015-06-30	2016-09-06	10-K	16-002894
4	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeInc...	$1.2M	2015-06-30	2016-09-06	10-K	16-002894
5	income tax	us-gaap:IncomeTaxExpenseBenefit	$132,000	2015-06-30	2016-09-06	10-K	16-002894
6	total debt	us-gaap:LongTermDebt	$1.3M	2015-06-30	2016-09-06	10-K	16-002894
7	book equity	us-gaap:StockholdersEquity	$13.9M	2015-06-30	2017-09-05	10-K	17-001106
8	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	$3.6M	2015-06-30	2015-09-15	10-K	15-001220
9	total debt	us-gaap:LongTermDebt	$1.3M	2014-06-30	2015-09-15	10-K	15-001220
10	book equity	us-gaap:StockholdersEquity	$12.7M	2014-06-30	2015-09-15	10-K	15-001220
11	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	$1.5M	2014-06-30	2015-09-15	10-K	15-001220
12	net income	us-gaap:NetIncomeLoss	$11.3M	2026-06-30	2026-08-25	10-K	26-028914
13	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$9.7M	2026-06-30	2026-08-25	10-K	26-028914
14	assets	us-gaap:Assets	$53.8M	2025-06-30	2026-08-25	10-K	26-028914
15	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$73.8M	2026-06-30	2026-08-25	10-K	26-028914
16	gross profit	us-gaap:GrossProfit	$50.0M	2025-06-30	2026-08-25	10-K	26-028914
17	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$64.0M	2025-06-30	2026-08-25	10-K	26-028914
18	gross profit	us-gaap:GrossProfit	$41.7M	2024-06-30	2025-08-26	10-K	25-027761

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

19	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$54.7M	2024-06-30	2025-08-26	10-K	25-027761
20	gross profit	us-gaap:GrossProfit	$36.5M	2023-06-30	2024-08-27	10-K	24-000422
21	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$48.1M	2023-06-30	2024-08-27	10-K	24-000422
22	gross profit	us-gaap:GrossProfit	$31.4M	2022-06-30	2023-08-22	10-K	23-000380
23	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$41.7M	2022-06-30	2023-08-22	10-K	23-000380
24	current assets	us-gaap:AssetsCurrent	$57.4M	2026-06-30	2026-08-25	10-K	26-028914
25	current liabilities	us-gaap:LiabilitiesCurrent	$12.2M	2026-06-30	2026-08-25	10-K	26-028914
26	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	$28.6M	2026-06-30	2026-08-25	10-K	26-028914
27	operating income	us-gaap:OperatingIncomeLoss	$13.9M	2026-06-30	2026-08-25	10-K	26-028914
28	book equity	us-gaap:StockholdersEquity	$54.0M	2026-06-30	2026-08-25	10-K	26-028914
29	liabilities	us-gaap:Liabilities	$12.3M	2026-06-30	2026-08-25	10-K	26-028914
30	depreciation amortization	us-gaap:Depreciation	$613,304	2015-06-30	2016-09-06	10-K	16-002894
31	interest expense	us-gaap:InterestExpense	$85,710	2015-06-30	2015-09-15	10-K	15-001220
32	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$1.3M	2026-06-30	2026-08-25	10-K	26-028914
33	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$11.4M	2025-06-30	2026-08-25	10-K	26-028914
34	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$262,000	2025-06-30	2026-08-25	10-K	26-028914
35	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$9.1M	2024-06-30	2025-08-26	10-K	25-027761
36	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$287,000	2024-06-30	2025-08-26	10-K	25-027761
37	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$1.3M	2023-06-30	2024-08-27	10-K	24-000422
38	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$1.6M	2023-06-30	2024-08-27	10-K	24-000422
39	depreciation amortization	us-gaap:Depreciation	$868,000	2026-06-30	2026-08-25	10-K	26-028914
40	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeInc...	$14.4M	2026-06-30	2026-08-25	10-K	26-028914
41	income tax	us-gaap:IncomeTaxExpenseBenefit	$3.1M	2026-06-30	2026-08-25	10-K	26-028914
42	current assets	us-gaap:AssetsCurrent	$45.1M	2025-06-30	2026-08-25	10-K	26-028914
43	current liabilities	us-gaap:LiabilitiesCurrent	$10.5M	2025-06-30	2026-08-25	10-K	26-028914
44	assets	us-gaap:Assets	$52.2M	2024-06-30	2025-08-26	10-K	25-027761
45	assets	us-gaap:Assets	$45.8M	2023-06-30	2024-08-27	10-K	24-000422
46	shares outstanding	dei:EntityCommonStockSharesOutstanding	8,366,163	2026-08-19	2026-08-25	10-K	26-028914
47	shares outstanding	dei:EntityCommonStockSharesOutstanding	8,349,176	2025-08-20	2025-08-26	10-K	25-027761

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.